Proactive Investors - Run By Investors For Investors

ANGLE ground-breaking liquid biopsy to be used in lung cancer study

The Partsortix system will be used in research being carried out by the Hellenic Oncology Research Group
doctors inspecting lung x-ray
Lung cancer has the highest mortality rate of all cancers and there are 2.1mln new cases each year

ANGLE PLC’s (LON:AGL, OTCQX:ANPCY) ground-breaking liquid biopsy system will be incorporated into a clinical study to provide an early warning of relapse among patients being treated for non-small cell lung cancer.

The Partsortix system will be used in research being carried out by the Hellenic Oncology Research Group and will be deployed to track circulating tumour DNA, fragments of dead cancer cells and circulating tumour cells (CTCs).

A total of 50 operable early-stage patients will have blood drawn prior to surgery, one month after the operation and then every three to six months until relapse. 

CTC evaluation is being undertaken by the University of Athens, lead by Professor Evi Lianidou, and the latest collaboration builds on work by the same team using Parsortix in research on head and neck cancer.

 "This is another example of ANGLE's product based leveraged R&D approach delivering key benefits with a major study, which is being developed, executed and funded by a leading customer,” said ANGLE chief executive Andrew Newland. 

“The high incidence and mortality rates of lung cancer create a pressing need for repeat biopsies to allow personalised medicine and we hope that our Parsortix liquid biopsy system can play a key role in delivering this to the benefit of patients, opening new markets for ANGLE."

Shares in ANGLE held steady at 67p in late afternoon trading on Friday.

 -- Adds share price --

View full AGL profile View Profile

ANGLE PLC Timeline

Related Articles

September 28 2018
The biotech group revealed it had brought in $9.1mln via an oversubscribed placing
A paper rocket is ready to launch on a surgeon's scissors
March 28 2019
The company hopes to improve its share price with ADAPT technology successes.
test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use